OSTX

OS Therapies Inc

Phase 1 AI-extracted

OST-504

castration resistant prostate cancer

Resolved

7days ago

Phase 1 readout · ~ Jun 30, 2026 estimated

What's at stake Phase 1 trial results for OST-504 in castration resistant prostate cancer are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“OST-504 Phase 1b castration resistant prostate cancer trial biomarker analysis to mirror OST-HER2 Phase 2b osteosarcoma biomarker analysis.”

Add to calendar Post on X Reddit

Provenance